$150.79
▼ -0.1% Today
as of Sep 4, 16:49 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 3
● 22
▼ 0
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
Overview
52-week range
$108
$157
87% of range
Avg surprise (last 3)
+3.3%
Avg reaction (last 2)
-0.9%
0% positive
Latest IV / EM
56%
EM ±2.4% · $150 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-8.45 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $2.03 | $1.89 | +7.4% | +12.2% | -1.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $2.43 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $2.01 | $1.95 | +3.1% | — | — | earnings |
| Thu Apr 24, 2025 | Mar/2025 | $1.81 | $1.82 | -0.6% | — | -0.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $1.00 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $1.29 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-3.34 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.73 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.83 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $0.80 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.80B | $6.96B | — | $7.77B | $7.08B | $6.67B | — | $7.54B |
| Cost of revenue | $1.58B | $1.45B | — | $1.57B | $1.50B | $1.54B | — | $1.57B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-10.39B | $2.59B | — | $3.33B | $2.47B | $2.24B | — | $888M |
| Net income | $-10.50B | $2.02B | — | $3.05B | $1.96B | $1.31B | — | $1.25B |
| EPS (diluted) | $-8.45 | $1.61 | — | $2.43 | $1.56 | $1.04 | — | $1.00 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Inventory | $1.95B | $1.91B | $1.77B | $1.78B | $1.82B | $1.76B | $1.71B | $1.87B |
| Total current assets | $13.95B | $18.64B | $18.34B | $17.87B | $14.72B | $16.90B | $19.17B | $14.78B |
| Total assets | $49.36B | $56.28B | $59.02B | $58.53B | $55.72B | $56.43B | $58.99B | $54.52B |
| Long-term debt | $23.83B | $20.86B | $22.13B | $22.14B | $22.14B | $22.15B | $24.90B | $21.44B |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $11.83B | $23.43B | $22.70B | $21.54B | $19.59B | $19.08B | $19.33B | $18.39B |